Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06083688

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Status
Active Not Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
1,000 (estimated)
Sponsor
Liverpool School of Tropical Medicine · Academic / Other
Sex
All
Age
6 Months
Healthy volunteers
Accepted

Summary

This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ). Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.

Detailed description

Students attending primary school in rural Blantyre District, Malawi will be offered enrollment in this study. The intervention will be conducted every 6-weeks during the school terms which coincide with peak malaria transmission. Students in the IPT-DP arm will be treated with with dihydroartemisinin-piperaquine (DP) (females less than 13 years old and all males) or chloroquine (females 13 years old or older). Students in the IPT-SPAQ arm will be treated with sulfadoxine-pyrimethamine plus amodiaquine (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older). Students in the all arms will receive routine malaria education.

Conditions

Interventions

TypeNameDescription
DRUGDihydroartemisinin-PiperaquineTreatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
DRUGChloroquineTreatment will be with CQ alone if female and 13 years old or older in both intervention arms.
DRUGSulfadoxine-pyrimethamine-amodiaquineTreatment in Arm 2 (females less than 13 years old and all males).

Timeline

Start date
2024-10-14
Primary completion
2025-07-31
Completion
2026-01-01
First posted
2023-10-16
Last updated
2025-11-19

Locations

1 site across 1 country: Malawi

Source: ClinicalTrials.gov record NCT06083688. Inclusion in this directory is not an endorsement.